Skip to main content
. 2021 Jul 6;25(11):1231–1239. doi: 10.1007/s10157-021-02100-0

Table 3.

Classifications

Variables, n (%) n = 1630
Gender, male 843 (51.7)
 Female 787 (48.3)
Age group
  ≤ 19 1 (0.1)
 20–29 42 (2.6)
 30–39 223 (13.7)
 40–49 615 (37.7)
 50–59 417 (25.6)
 60–69 246 (15.1)
 70–79 81 (5.0)
  ≥ 80 5 (0.3)
CKD stage
 G1 62 (3.8)
 G2 299 (18.3)
 G3a 328 (20.1)
 G3b 440 (27.0)
 G4 490 (30.1)
 G5 9 (0.6)
 Unknown 2 (0.1)
Total kidney volume
  < 750 mL 4 (0.2)
  ≥ 750– < 1500 mL 369 (22.6)
  ≥ 1500– < 3000 mL 403 (24.7)
  ≥ 3000– < 4500 mL 139 (8.5)
  ≥ 4500– < 6000 mL 31 (1.9)
  ≥ 6000 mL 19 (1.2)
 Missing or before Day -90 665 (40.8)
Mayo classification
 1A 0 (0.0)
 1B 152 (9.3)
 1C 317 (19.4)
 1D 242 (14.8)
 1E 90 (5.5)
 Missing 829 (50.9)

CKD chronic kidney disease, SD standard deviation

Baseline value is defined as the last available value on or prior to the first dose date

CKD stages were based on eGFR value (mL/min/1.73 m2): G1 (≥ 90), G2 (60 to 89), G3a (45 to 59), G3b (30 to 44), G4 (15 to 29), and G5 (< 15)

The baseline values for TKV and eGFR are defined as the last available values, on or prior to the first dose, extending back to Day -90